Advertisement

Topics

Latest "Achillion Reports Preliminary Proof Concept With 4471 Treatment" News Stories

08:23 EST 20th February 2019 | BioPortfolio

Here are the most relevant search results for "Achillion Reports Preliminary Proof Concept With 4471 Treatment" found in our extensive news archives from over 250 global news sources.

More Information about Achillion Reports Preliminary Proof Concept With 4471 Treatment on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Achillion Reports Preliminary Proof Concept With 4471 Treatment for you to read. Along with our medical data and news we also list Achillion Reports Preliminary Proof Concept With 4471 Treatment Clinical Trials, which are updated daily. BioPortfolio also has a large database of Achillion Reports Preliminary Proof Concept With 4471 Treatment Companies for you to search.

Showing "Achillion Reports Preliminary Proof Concept With 4471 Treatment" News Articles 1–25 of 22,000+

Wednesday 20th February 2019

Medtronic Announces U.S. Commercial Launch of Deep Brain Stimulation for Medically-Refractory Epilepsy

With Official Launch and First Implant, Several Health Insurers Now Consider DBS Therapy for Epilepsy a Covered Indication DUBLIN - February 20, 2019 - Medtronic plc (NYSE:MDT) today announced both the U.S. launch of Deep Brain Stimulation (DBS) for medically-refractory epilepsy and the first commercially implanted patient at Emory University in Atlanta, Ga. According to the Epilep...


Novus Therapeutics to Participate in the 8th Annual SVB Leerink Global Healthcare Conference

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that the company will participate at the 8th Annual SVB Leerink Healthcare Conference on Thursday, February 28, 2019 at the Lotte New York Palace, New York. About...

Engineer Creates a Guide to the internal Human Operating System (iHOS) to Defrag Life’s Problem Areas in New Book

Norbert Soski, author of "Only Human: Guide to Our internal Human Operating System (iHOS) and Achieving a Better Life," will speak to the Naturopathic Medical Student Association at the National University of Natural Medicine (NUNM) in Portland, Oregon on March 1 at 8 a.m. LOS ANGELES (PRWEB) February 20, 2019 After working as an engineer for some of the top defense corporations in Amer...


ReNeuron shares spike 20% after it provides encouraging update to phase II eye disease trial

The first three patients in a group taking part in the phase II portion of the study were able on average able to read an additional three lines of on the standard ETDRS eye chart after receiving treatment

Stone Waterproofing Agent Global Market Research and Forecast, 20152025 [Report Updated: 01011970] Prices from USD $2200

SummaryThe Stone Waterproofing Agent report provides an independent information about the Stone Waterproofing Agent industry supported by extensive research on factors such as industry segmentssize trends, inhibitors, dynamics, drivers, opportunities challenges, environment policy, cost overview, porter's five force analysis, and key companies profiles including business overview and recent d...

Point of Care CT Imaging Systems Global Market Research and Forecast, 20152025 [Report Updated: 01011970] Prices from USD $2200

SummaryThe Point of Care CT Imaging Systems report provides an independent information about the Point of Care CT Imaging Systems industry supported by extensive research on factors such as industry segmentssize trends, inhibitors, dynamics, drivers, opportunities challenges, environment policy, cost overview, porter's five force analysis, and key companies profiles including business overvie...

Platinum Group Metals Global Market Research and Forecast, 20152025 [Report Updated: 01011970] Prices from USD $2200

SummaryThe Platinum Group Metals report provides an independent information about the Platinum Group Metals industry supported by extensive research on factors such as industry segmentssize trends, inhibitors, dynamics, drivers, opportunities challenges, environment policy, cost overview, porter's five force analysis, and key companies profiles including business overview and recent developme...

Only 52% of EMS Practitioners Report a Very High Level of Confidence in Recognizing Sepsis – the Third Leading Cause of Death in the United States

Sepsis Alliance and NAEMT survey finds that increased sepsis education is urgently needed for EMS personnel. SAN DIEGO (PRWEB) February 20, 2019 Today, Sepsis Alliance and the National Association of Emergency Medical Technicians (NAEMT) released the results of their Sepsis and EMS Survey. The survey results find that only 52% of the more than 1,300 EMT practitioners interviewed are very confiden...

Entertainment and AV Services for Better Patient Experience Valued by Dialysis Clinic Patients

TeleHealth Services Provides AV and Entertainment Services to 3,000th U.S. Dialysis Clinic for “Home Away from Home” Experience TeleHealth Services recently completed its 3,000th installation of audiovisual and entertainment systems serving dialysis centers and their patients.

$AGIO FDA Acceptance of sNDA for TIBSOVO® (ivosidenib) for the Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation Not Eligible for Standard Therapy. Pdufa June 21, 2019

$AGIO FDA Acceptance of sNDA for TIBSOVO® (ivosidenib) for the Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation Not Eligible for Standard Therapy. Pdufa June 21, 2019

Newron Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Stefan Weber, CEO, will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York, NY on Wednesday, Februa...

AVEO Oncology to Present at the 8th Annual SVB Leerink Global Healthcare Conference

AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York on Wednesday, February 27, 2019 at 2:30 p.m. Eastern Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’...

Verastem Oncology Announces Key Management Appointments

Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced several key appointments to its management team. The recent additions to the Verastem Oncology senior team include Amy C. Ca...

Rocket Pharmaceuticals Announces Participation in Fireside Chat at the 8th Annual SVB Leerink Global Healthcare Conference

Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announces that Gaurav Shah, M.D., Chief Executive Officer and President of Rocket, will participate in a fireside chat at the 8th Annual SVB Leerink Global Healthcare Conference in New York City. The fireside chat will take pla...

Cardiovascular Systems, Inc. to Present at the 8th Annual SVB Leerink Global Healthcare Conference

On Wednesday, February 27, 2019, Cardiovascular Systems’ (NASDAQ: CSII) Chairman, President and Chief Executive Officer, Scott Ward, and Chief Operating Officer, Rhonda Robb, will present at the 8th Annual SVB Leerink Global Healthcare Conference at 3:00 p.m. Eastern Time. You may access the live audio webcast, as well as a replay, on the ...

Developments in Weight Loss Technology Featured on Innovations Television Series

Research in olfaction regulation points to appetite suppression, healthier eating, and weight loss. JUPITER, Fla. (PRWEB) February 20, 2019 In this episode, the award-winning series, Innovations with Ed Begley, Jr. will focus on weight loss and weight management and how recent developments in the ability to affect olfactory regulation are helping people lose weight and prefer healthy food. This s...

Murrieta Genomics and SeqOnce Biosciences Team to Simplify and Commercialize Next Generation Sequencing Sample Preparation

Murrieta Genomics will showcase SeqOnce’s technology and products in its incubator facility, providing information and demonstrations to potential customers. Murrieta Genomics will also assist SeqOnce with product development by testing and using its products in the Murrieta laboratory. MURRIETA, Calif. (PRWEB) February 20, 2019 Murrieta Genomics, the genomic sequencing business incubator and S...

Extracorporeal Cardiopulmonary Support in Acute High-risk PE

A new study explores the potential role of extracorporeal membrane oxygenation for the supportive treatment of high-risk PE patients. Is there sufficient evidence to recommend this procedure? European Heart Journal

Biologic Adjuvants for Osteochondral Lesions of the Talus

Learn more about the available biologic adjuvants to augment treatment of osteochondral lesions of the talus. Journal of the American Academy of Orthopaedic Surgeons

Improving Hepatitis C DAA Access and Uptake

How does treatment with DAAs alter the social and individual experience of living with hepatitis C? This commentary highlights the need for an individual focus for outcome measures. Journal of Viral Hepatitis

Vitamin D Deficiency and Treatment vs Infection Risk in ESRD

In what ways might vitamin D status and the use of supplements impact the risk of infection among ESRD patients receiving long-term dialysis? Nephrology Dialysis Transplantation

Optic Neuritis as Initial Presentation of Limbic Encephalitis

This case highlights autoimmune encephalitis as an important differential diagnosis in the management of optic neuritis not associated with MS or other demyelinating diseases. Journal of Medical Case Reports

$MNK Interim Analysis Results for Therakos® Platform P3 Clinical Trial in Treatment of Pediatric Patients with Steroid Refractory Acute #GVHD https://www.prnewswire.com/news-releases/mallinckrodt-announces-interim-analysis-results-for-therakos-platform-

$MNK Interim Analysis Results for Therakos® Platform P3 Clinical Trial in Treatment of Pediatric Patients with Steroid Refractory Acute #GVHD https://www.prnewswire.com/news-releases/mallinckrodt-announces-interim-analysis-results-for-therakos-platform-phase-3-clinical-trial-in-treatment-of-

Merck: FDA Grants Priority Review To SBLA For Keytruda Monotherapy

Drug maker Merck & Co. Inc. (MRK) said Tuesday that the U.S. Food and Drug Administration has accepted and granted priority review for a new supplemental Biologics License Application or sBLA for Keytruda, Merck's anti-PD-1 therapy, as monotherapy for the treatment of patients with advanced small cell lung cancer (SCLC) whose disease has progressed after two or more lines of prior therapy.

$MRK FDA Grants Priority Review to sBLA for KEYTRUDA® Monotherapy for Third-Line Treatment of Patients with Advanced #SCLC. Pdufa June, 2019 https://www.businesswire.com/news/home/20190220005296/en/FDA-Grants-Priority-Review-Merck%E2%80%99s-Supplemental-

$MRK FDA Grants Priority Review to sBLA for KEYTRUDA® Monotherapy for Third-Line Treatment of Patients with Advanced #SCLC. Pdufa June, 2019 https://www.businesswire.com/news/home/20190220005296/en/FDA-Grants-Priority-Review-Merck%E2%80%99s-Supplemental-Biologics …


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks